Imagion Biosystems (ASX:IBX): Big things come in nano packages, page-128

I doubt it

this trial was about safety, which was a given, which is already factored into the price. The simple first step.

bobs lack of ability to execute will hold the SP down for long into the pivotal trial.

getting positive phase 1 results doesn’t forgive the debacle this company has become. The market wants to know about efficacy, and given bobs track record that is many many years away. That timing also provides many CR opportunities in the future before trials are complete.

it’s going to take a lot of news and progress to get out of the hole Bob has dug for this company.

such a shame, blockbuster tech handed to a marketing executive with no record of successfully completing a clinical trials.

someone tell Elon, he might be able to salvage bob’s disaster with a bit of Twitter loose change.